CN107149146A - Lozenge containing phosphatidylserine and preparation method thereof - Google Patents
Lozenge containing phosphatidylserine and preparation method thereof Download PDFInfo
- Publication number
- CN107149146A CN107149146A CN201710446295.9A CN201710446295A CN107149146A CN 107149146 A CN107149146 A CN 107149146A CN 201710446295 A CN201710446295 A CN 201710446295A CN 107149146 A CN107149146 A CN 107149146A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- consumption
- mixture
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title claims abstract description 36
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 239000007937 lozenge Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000010438 heat treatment Methods 0.000 claims abstract description 28
- 239000000843 powder Substances 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 229920001214 Polysorbate 60 Polymers 0.000 claims abstract description 13
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 12
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 12
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 12
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000008101 lactose Substances 0.000 claims abstract description 12
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 12
- 229940041616 menthol Drugs 0.000 claims abstract description 12
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000010447 xylitol Nutrition 0.000 claims abstract description 12
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 12
- 229960002675 xylitol Drugs 0.000 claims abstract description 12
- 239000000811 xylitol Substances 0.000 claims abstract description 12
- 235000012907 honey Nutrition 0.000 claims abstract description 10
- 102000011420 Phospholipase D Human genes 0.000 claims abstract description 9
- 108090000553 Phospholipase D Proteins 0.000 claims abstract description 9
- 235000019871 vegetable fat Nutrition 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 5
- 229960001375 lactose Drugs 0.000 claims abstract description 5
- 238000000638 solvent extraction Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- 235000004400 serine Nutrition 0.000 abstract description 11
- 150000003355 serines Chemical class 0.000 abstract 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 37
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 35
- 239000003921 oil Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of lozenge containing phosphatidylserine and preparation method thereof, the preparation method includes：Mixture A is obtained after DHA algal oil, polyoxyethylene sorbitan monoleate and water are mixed；Mixture B will be obtained after the mixing of L serines, phospholipase D and cushioning liquid, heating；Through solvent extraction after mixture A and mixture B is mixed, the phosphatidylserine rich in DHA is obtained；Heated after obtained phosphatidylserine, vegetable fat powder, xylitol, lactose, menthol, maltodextrin, honey element and water are mixed, filter residue M is obtained after filtering；By the filter residue M through being concentrated under reduced pressure, dry after obtain medicinal powder, by the medicinal powder carry out tabletting, obtain the lozenge；DHA and PS is rich in obtained lozenge, passes through DHA and PS synergy, it is possible to increase DHA stability, promotes human body to absorb it.
Description
Technical field
The present invention relates to field of food preparation, in particular it relates to lozenge containing phosphatidylserine and preparation method thereof.
Background technology
Phosphatidylserine (Phosphatidylserine, PS) be mammalian cell membrane phosphatide important composition into
Point, especially in brain tissue, PS can successfully pass through blood-brain barrier, and a few minutes after being absorbed can enter intracerebral, its
It is closely related with the brain function such as cognition, mood, study, memory, it has been applied to improve Alzheimer disease, treatment at present depressed
In terms of disease, alleviation stress and physical fatigue.Docosahexaenoic acid (docosahexaenoicacid, DHA) is in brain tonic
There is remarkable effect in terms of intelligence development and protection eyesight, free DHA is unstable, oxidizable, and independent take can increase stomach and intestine
Burden.How DHA and PS to be synthesized, and be applied in food manufacture field, further to improve human body to DHA's and PS
The problem of absorption is urgent need to resolve of the present invention.
The content of the invention
It is rich in obtained lozenge it is an object of the invention to provide a kind of lozenge containing phosphatidylserine and preparation method thereof
Containing DHA and PS, pass through DHA and PS synergy, it is possible to increase DHA stability, promote human body to absorb it.
To achieve these goals, it is described the invention provides a kind of preparation method of the lozenge containing phosphatidylserine
Preparation method includes：
(1) mixture A is obtained after mixing DHA algal oil, polyoxyethylene sorbitan monoleate and water；
(2) mixture B will be obtained after the mixing of Serine, phospholipase D and cushioning liquid, heating；
(3) through solvent extraction after mixture A and mixture B is mixed, the phosphatidylserine rich in DHA is obtained；
(4) phosphatidylserine, vegetable fat powder, xylitol, lactose, menthol, maltodextrin, the sweet tea for obtaining step (3)
Heated after sweet element and water mixing, filter residue M is obtained after filtering；
(5) by the filter residue M through being concentrated under reduced pressure, dry after obtain medicinal powder, the medicinal powder is subjected to tabletting, described contain is obtained
Piece.
Present invention also offers a kind of lozenge containing phosphatidylserine, the lozenge is made by above-mentioned preparation method.
By above-mentioned technical proposal, the invention provides a kind of lozenge containing phosphatidylserine and preparation method thereof, institute
Stating preparation method includes：Mixture A is obtained after DHA algal oil, polyoxyethylene sorbitan monoleate and water are mixed；By Serine, phospholipase D and
Mixture B is obtained after cushioning liquid mixing, heating；Through solvent extraction after mixture A and mixture B is mixed, obtain being rich in DHA
Phosphatidylserine；By obtained phosphatidylserine, vegetable fat powder, xylitol, lactose, menthol, maltodextrin, honey element
Heated with after water mixing, filter residue M is obtained after filtering；By the filter residue M through being concentrated under reduced pressure, dry after obtain medicinal powder, by the medicine
Powder carries out tabletting, obtains the lozenge；It is oxidizable because free DHA is unstable, and independent take can increase stomach and intestine burden,
By the synthesis to DHA and PS, increase DHA stability, by both synergies, human body can be promoted in lozenge
DHA and PS absorption so that obtained lozenge possesses alleviation stress and physical fatigue, the function of brain tonic and intelligence development.
Other features and advantages of the present invention will be described in detail in subsequent embodiment part.
Embodiment
The embodiment to the present invention is described in detail below.It should be appreciated that described herein specific
Embodiment is merely to illustrate and explain the present invention, and is not intended to limit the invention.
The end points and any value of disclosed scope are not limited to the accurate scope or value herein, these scopes or
Value should be understood to comprising the value close to these scopes or value.For number range, between the endpoint value of each scope, respectively
It can be combined with each other between the endpoint value of individual scope and single point value, and individually between point value and obtain one or more
New number range, these number ranges should be considered as specific open herein.
The invention provides a kind of preparation method of the lozenge containing phosphatidylserine, the preparation method includes：
(1) mixture A is obtained after mixing DHA algal oil, polyoxyethylene sorbitan monoleate and water；
(2) mixture B will be obtained after the mixing of Serine, phospholipase D and cushioning liquid, heating；
(3) through solvent extraction after mixture A and mixture B is mixed, the phosphatidylserine rich in DHA is obtained；
(4) phosphatidylserine, vegetable fat powder, xylitol, lactose, menthol, maltodextrin, the sweet tea for obtaining step (3)
Heated after sweet element and water mixing, filter residue M is obtained after filtering；
(5) by the filter residue M through being concentrated under reduced pressure, dry after obtain medicinal powder, the medicinal powder is subjected to tabletting, described contain is obtained
Piece.
The present invention it is a kind of preferred embodiment in, in order to further improve suction of the human body to DHA in lozenge and PS
Receive, relative to the water of 100 parts by weight, the consumption of the DHA algal oil is 0.2-0.6 parts by weight, the consumption of the polyoxyethylene sorbitan monoleate
For 2-8 parts by weight, relative to the cushioning liquid of 100 parts by weight, the consumption of the Serine is 10-20 parts by weight, the phosphorus
The consumption of lipase D is 0.5-5.5 parts by weight；
Relative to the xylitol of 100 parts by weight, the consumption of the phosphatidylserine is 1-3 parts by weight, the vegetable fat powder
Consumption be 5-15 parts by weight, the consumption of the lactose is 10-20 parts by weight, and the consumption of the menthol is 1-10 parts by weight,
The consumption of the maltodextrin is 0.5-2 parts by weight, and the consumption of the honey element is 2-5 parts by weight, and the consumption of the water is
150-250 parts by weight.
The present invention it is a kind of preferred embodiment in, in order to further improve DHA and PS combined coefficient, step
(3) mixture A and mixture B is 1 according to volume ratio in:20-40 is mixed.
The present invention it is a kind of preferred embodiment in, in order that obtained phosphatidylserine purity is higher, institute
Cushioning liquid is stated to be made up of chloroform and ethanol, and the volume ratio of chloroform and ethanol is 1:2-5.
The present invention it is a kind of preferred embodiment in, in order that obtained phosphatidylserine purity is higher, step
Suddenly the temperature of heating is 40-60 DEG C in (2), and the time of heating is 4-8h.
The present invention it is a kind of preferred embodiment in, in order to obtain purity higher phosphatidyl rich in DHA thread ammonia
Acid, the solvent includes ethanol, ether and water；And relative to the water of 100 parts by weight, the consumption of the ethanol is 20-40 weight
Part, the consumption of the ether is 10-20 parts by weight.
The present invention it is a kind of preferred embodiment in, in order that can preferably mix between raw material, step (4)
The temperature of middle heating is 60-80 DEG C, and the time of heating is 5-10min.
Present invention also offers a kind of lozenge containing phosphatidylserine, the lozenge is made by above-mentioned preparation method.
The present invention will be described in detail by way of examples below.In following examples, in following examples, DHA algal
The commercially available product that oil provides for Qingdao Weilan Biology Group Co., Ltd.；Polyoxyethylene sorbitan monoleate provides for Science and Technology Ltd. of Beijing Lingbao City
Commercially available product；The commercially available product that Serine provides for the outstanding Bioisystech Co., Ltd in Shanghai three；Phospholipase D is that moral is filled in (China) admittedly
The commercially available product that company provides.
Embodiment 1
Mixture A is obtained after 0.2gDHA algae oils, 2g polyoxyethylene sorbitan monoleates and 100g water are mixed；By 10gL- serines,
(cushioning liquid is made up of chloroform and ethanol, and the volume ratio of chloroform and ethanol is 1 for 0.5g phospholipase Ds and 100g cushioning liquid:2)
Mixture B is obtained after mixing, heating (temperature of heating is 40 DEG C, and the time of heating is 4h)；Mixture A and mixture B are mixed
(mixture A and mixture B are 1 according to volume ratio for conjunction:20 are mixed) by solvent, (solvent is by 20-40g ethanol, 10-20g
Ether and 100g water are mixed to get) extraction, obtain the phosphatidylserine rich in DHA；By obtained phosphatidylserine 1g, plant
Heated after fat end 5g, xylitol 100g, lactose 10g, menthol 1g, maltodextrin 0.5g, honey element 2g and water 150g mixing (plus
The temperature of heat is 60 DEG C, and the time of heating is 5min), filter residue M is obtained after filtering；By the filter residue M through being concentrated under reduced pressure, dry after
Medicinal powder is obtained, the medicinal powder is subjected to tabletting, the lozenge A1 is obtained.
Embodiment 2
Mixture A is obtained after 0.6gDHA algae oils, 8g polyoxyethylene sorbitan monoleates and 100g water are mixed；By 20gL- serines,
(cushioning liquid is made up of chloroform and ethanol, and the volume ratio of chloroform and ethanol is 1 for 5.5g phospholipase Ds and 100g cushioning liquid:5)
Mixture B is obtained after mixing, heating (temperature of heating is 60 DEG C, and the time of heating is 8h)；Mixture A and mixture B are mixed
(mixture A and mixture B are 1 according to volume ratio for conjunction:40 are mixed) by solvent (solvent by 40g ethanol, 20g ether and
100g water is mixed to get) extraction, obtain the phosphatidylserine rich in DHA；By obtained phosphatidylserine 3g, vegetable fat powder
Heat (heating after 15g, xylitol 100g, lactose 20g, menthol 10g, maltodextrin 2g, honey element 5g and water 250g mixing
Temperature is 80 DEG C, and the time of heating is 10min), filter residue M is obtained after filtering；By the filter residue M through being concentrated under reduced pressure, dry after
To medicinal powder, the medicinal powder is subjected to tabletting, the lozenge A2 is obtained.
Embodiment 3
Mixture A is obtained after 0.4gDHA algae oils, 5g polyoxyethylene sorbitan monoleates and 100g water are mixed；By 15gL- serines,
(cushioning liquid is made up of chloroform and ethanol, and the volume ratio of chloroform and ethanol is 1 for 3.5g phospholipase Ds and 100g cushioning liquid:3)
Mixture B is obtained after mixing, heating (temperature of heating is 50 DEG C, and the time of heating is 6h)；Mixture A and mixture B are mixed
(mixture A and mixture B are 1 according to volume ratio for conjunction:30 are mixed) by solvent (solvent by 30g ethanol, 15g ether and
100g water is mixed to get) extraction, obtain the phosphatidylserine rich in DHA；By obtained phosphatidylserine 2g, vegetable fat powder
Heating (heating after 10g, xylitol 100g, lactose 15g, menthol 5g, maltodextrin 1.5g, honey element 3g and water 200g mixing
Temperature be 70 DEG C, time of heating is 7min), filter residue M is obtained after filtering；By the filter residue M through being concentrated under reduced pressure, dry after
To medicinal powder, the medicinal powder is subjected to tabletting, the lozenge A3 is obtained.
Comparative example 1
It is prepared by the method according to embodiment 3, unlike, the water relative to 100g, the consumption of the DHA algal oil is
0.1g, the consumption of the polyoxyethylene sorbitan monoleate is 1g, the cushioning liquid relative to 100g, and the consumption of the Serine is 7g, institute
The consumption for stating phospholipase D is 0.2g；Xylitol relative to 100g, the consumption of the phosphatidylserine is 0.5g, the plant
The consumption at fat end is 3g, and the consumption of the lactose is 5g, and the consumption of the menthol is 0.5g, and the consumption of the maltodextrin is
0.2g, the consumption of the honey element is 1g, and the consumption of the water is 120g, obtains the lozenge D1.
Comparative example 2
It is prepared by the method according to embodiment 3, unlike, the water relative to 100g, the consumption of the DHA algal oil is
0.8g, the consumption of the polyoxyethylene sorbitan monoleate is 10g, the cushioning liquid relative to 100g, and the consumption of the Serine is 25g,
The consumption of the phospholipase D is 7g；Xylitol relative to 100g, the consumption of the phosphatidylserine is 3.5g, the plant
The consumption at fat end is 20g, and the consumption of the lactose is 25g, and the consumption of the menthol is 15g, the consumption of the maltodextrin
For 3g, the consumption of the honey element is 6g, and the consumption of the water is 280g, obtains the lozenge D2.
Table 1
| Embodiment is numbered | PS synthetic ratios (%) | DHA content (g/L) in lozenge |
| Embodiment 1 | 96 | 2.4 |
| Embodiment 2 | 97 | 2.1 |
| Embodiment 3 | 95 | 2.4 |
| Comparative example 1 | 85 | 1.7 |
| Comparative example 2 | 84 | 1.2 |
It can be seen that by above table data in preparation method within the scope of the present invention, PS synthetic ratio is higher, reaches
To 95-97%, DHA content is higher in obtained lozenge A1-A3, and in the preparation method outside the scope of the invention, PS conjunction
Relatively low into rate, DHA content is relatively low in obtained lozenge A1-A3.DHA and PS is rich in obtained lozenge, is passed through
DHA and PS synergy, it is possible to increase DHA stability, promotes human body to absorb it.
The preferred embodiment of the present invention described in detail above, still, the present invention are not limited in above-mentioned embodiment
Detail, in the range of the technology design of the present invention, a variety of simple variants can be carried out to technical scheme, this
A little simple variants belong to protection scope of the present invention.
It is further to note that each particular technique feature described in above-mentioned embodiment, in not lance
In the case of shield, can be combined by any suitable means, in order to avoid unnecessary repetition, the present invention to it is various can
The combination of energy no longer separately illustrates.
In addition, various embodiments of the present invention can be combined randomly, as long as it is without prejudice to originally
The thought of invention, it should equally be considered as content disclosed in this invention.
Claims (8)
1. a kind of preparation method of the lozenge containing phosphatidylserine, it is characterised in that the preparation method includes：
(1) mixture A is obtained after mixing DHA algal oil, polyoxyethylene sorbitan monoleate and water；
(2) mixture B will be obtained after the mixing of Serine, phospholipase D and cushioning liquid, heating；
(3) through solvent extraction after mixture A and mixture B is mixed, the phosphatidylserine rich in DHA is obtained；
(4) phosphatidylserine, vegetable fat powder, xylitol, lactose, menthol, maltodextrin, the honey element for obtaining step (3)
Heated with after water mixing, filter residue M is obtained after filtering；
(5) by the filter residue M through being concentrated under reduced pressure, dry after obtain medicinal powder, by the medicinal powder carry out tabletting, obtain the lozenge.
2. preparation method according to claim 1, wherein, relative to the water of 100 parts by weight, the consumption of the DHA algal oil
For 0.2-0.6 parts by weight, the consumption of the polyoxyethylene sorbitan monoleate is 2-8 parts by weight, relative to the cushioning liquid of 100 parts by weight, institute
The consumption for stating Serine is 10-20 parts by weight, and the consumption of the phospholipase D is 0.5-5.5 parts by weight；
Relative to the xylitol of 100 parts by weight, the consumption of the phosphatidylserine is 1-3 parts by weight, the use of the vegetable fat powder
Measure as 5-15 parts by weight, the consumption of the lactose is 10-20 parts by weight, and the consumption of the menthol is 1-10 parts by weight, described
The consumption of maltodextrin is 0.5-2 parts by weight, and the consumption of the honey element is 2-5 parts by weight, and the consumption of the water is 150-250
Parts by weight.
3. preparation method according to claim 1 or 2, wherein, mixture A and mixture B are according to volume ratio in step (3)
For 1:20-40 is mixed.
4. preparation method according to claim 3, wherein, the cushioning liquid is made up of chloroform and ethanol, and chloroform and
The volume ratio of ethanol is 1:2-5.
5. preparation method according to claim 4, wherein, the temperature of heating is 40-60 DEG C in step (2), heating when
Between be 4-8h.
6. preparation method according to claim 5, wherein, the solvent includes ethanol, ether and water；
And relative to the water of 100 parts by weight, the consumption of the ethanol is 20-40 parts by weight, and the consumption of the ether is 10-20 weights
Measure part.
7. preparation method according to claim 1, wherein, the temperature of heating is 60-80 DEG C in step (4), heating when
Between be 5-10min.
8. a kind of lozenge containing phosphatidylserine, it is characterised in that the lozenge is as described in any one in claim 1-7
Preparation method be made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710446295.9A CN107149146A (en) | 2017-06-14 | 2017-06-14 | Lozenge containing phosphatidylserine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710446295.9A CN107149146A (en) | 2017-06-14 | 2017-06-14 | Lozenge containing phosphatidylserine and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107149146A true CN107149146A (en) | 2017-09-12 |
Family
ID=59795326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710446295.9A Pending CN107149146A (en) | 2017-06-14 | 2017-06-14 | Lozenge containing phosphatidylserine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107149146A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177381A (en) * | 1995-11-08 | 1998-03-25 | 株式会社雅库路特本社 | Process for producing phosphatidylserines having polybasic unsaturated fatty acid and as side chain |
| CN105341909A (en) * | 2015-11-09 | 2016-02-24 | 苏州泽达兴邦医药科技有限公司 | Health care food used for improving memory and preparation method therefor |
| CN106086097A (en) * | 2016-06-08 | 2016-11-09 | 芜湖福民生物药业有限公司 | The preparation method of Phosphatidylserine |
| CN106509908A (en) * | 2015-09-12 | 2017-03-22 | 石家庄以岭药业股份有限公司 | Chewable tablets containing phosphatidylserine and preparation method thereof |
| CN106722978A (en) * | 2015-11-19 | 2017-05-31 | 徐州统食品工业有限公司 | A kind of health food for improving cognitive ability and memory |
-
2017
- 2017-06-14 CN CN201710446295.9A patent/CN107149146A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177381A (en) * | 1995-11-08 | 1998-03-25 | 株式会社雅库路特本社 | Process for producing phosphatidylserines having polybasic unsaturated fatty acid and as side chain |
| CN106509908A (en) * | 2015-09-12 | 2017-03-22 | 石家庄以岭药业股份有限公司 | Chewable tablets containing phosphatidylserine and preparation method thereof |
| CN105341909A (en) * | 2015-11-09 | 2016-02-24 | 苏州泽达兴邦医药科技有限公司 | Health care food used for improving memory and preparation method therefor |
| CN106722978A (en) * | 2015-11-19 | 2017-05-31 | 徐州统食品工业有限公司 | A kind of health food for improving cognitive ability and memory |
| CN106086097A (en) * | 2016-06-08 | 2016-11-09 | 芜湖福民生物药业有限公司 | The preparation method of Phosphatidylserine |
Non-Patent Citations (1)
| Title |
|---|
| 张芹等: "酶法合成富含二十二碳六烯酸的磷脂酰丝氨酸", 《中国食品学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103141604B (en) | Agilawood-level tea and preparation method thereof | |
| WO2020122398A1 (en) | Method for producing honey in which cinnamon distillate is mixed | |
| CN102450352A (en) | Rose tea | |
| CN110343589A (en) | A kind of glutinous rice health preserving wine and its brewage process adding traditional Chinese medicine ingredients | |
| CN104970051A (en) | Nontoxic mosquito-repellent incense liquid and preparation method thereof | |
| CN102908646A (en) | Grape flavor air freshening preparation | |
| CN107149146A (en) | Lozenge containing phosphatidylserine and preparation method thereof | |
| CN108042653A (en) | A kind of antifatigue inducing resuscitation plant cotton piece and its preparation process | |
| CN104825514A (en) | Lucid ganoderma and America ginseng capsule | |
| CN105031204B (en) | A kind of tranquilizing the mind composition | |
| CN103960404A (en) | Sealwort nourishing tea and preparation method thereof | |
| CN107343892A (en) | Traditional Chinese medicine oral liquid and preparation method thereof | |
| CN102125124A (en) | Traditional Chinese medicine health protection tea for preventing and treating hypertension | |
| CN105638926A (en) | Healthcare edible oil | |
| CN107156296A (en) | Yoghourt containing phosphatidylserine and preparation method thereof | |
| CN101744069A (en) | Compound wild jujube tea | |
| CN103351951A (en) | Cigarette essence capable of improving quality of cigarettes | |
| CN101240232B (en) | Fatigue resisting wine | |
| CN107260748A (en) | Traditional Chinese medicine oral liquid and preparation method thereof | |
| CN107318983A (en) | Milk powder containing phosphatidylserine and preparation method thereof | |
| KR101539993B1 (en) | A method for manufacturing soybean paste and soy sauce comprising oriental medicine | |
| CN107334008A (en) | Fruit beverage containing phosphatidylserine and preparation method thereof | |
| KR20100100144A (en) | Mokcho sap powder composition comprising lavender oil powder and mokcho sap patch using the same | |
| CN104872347A (en) | Burdock tea beverage and production method thereof | |
| CN104642632A (en) | Chrysanthemum and fructus lycii health-caring tea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170912 |